Objective: To assess how clinical pharmacist-led educational interventions affect lipid profile parameters and related clinical outcomes in cardiovascular disease-risk individuals. Methods: This systematic review completed as according to PRISMA 2020 principles. Searches were done on PubMed, ScienceDirect, ProQuest, Google Scholar, DOAJ, Scopus, and Web of Science. Studies examining impact of the pharmacists' educational initiatives on lipid levels were included. However, case reports, conference proceedings, and studies in other languages not in English, and studies lacking full-text access were excluded from the review. Following screening and eligibility assessment, a total of 33 papers were included out of the 1731 records found. These include cohort studies, pre-post investigations, and randomised controlled trials (RCTs). The methodological quality of the incorporated studies was estimated with the help of the Mixed Methods Appraisal Tool (MMAT 2018). Results: Positive changes in lipid profiles were shown by pharmacist-led educational initiatives, including reductions in LDL cholesterol, total cholesterol, and serum triglyceride levels. There were also many reports of improvements in blood pressure, lifestyle choices, glycaemic indices, HDL cholesterol (HDL-C), and medication adherence. Numerous studies demonstrated lower risk scores for cardiovascular disease (CVD) after pharmacist involvement. Clinical results were most significantly improved by interventions that incorporated medication reconciliation, lifestyle counselling, telepharmacy follow-ups, risk factor monitoring, and customised patient education. Conclusion: Through increased medication adherence, better patient awareness, and support for lifestyle adjustment, pharmacist-led educational programs greatly reduce the risk of CVD and enhanced lipid profiles. To enhance the management of chronic diseases, clinical chemists must be integrated into multidisciplinary care teams. To optimise advantages, future research should focus on standardised intervention models, cost-effectiveness assessment, and long-term cardiovascular outcome monitoring.
Saad S. Alqahtani (Fri,) studied this question.